Inclusion Criteria:

Histologically proven invasive breast cancer T1-4N0-3M0, pre- or
postmenopausal breast cancer patient treated with adjuvant chemotherapy or radiotherapy
within 4 months or patient who has started adjuvant endocrine therapy (antiestrogens,
aromatase inhibitors, LHRH agonists, or combinations) no later than 4 months earlier,age
from 35 to 68 years,signed informed consent prior to beginning protocol specific
procedures

Exclusion Criteria:

- Prior malignancy except basal cell carcinoma or in situ cervix carcinoma

- Male gender

- Haematogenous metastases (M1)

- No systemic adjuvant therapy

- Postmenopausal women treated with antiestrogens, tamoxifen or toremifene, adjuvant
treatment only (+/- radiotherapy)

- Pregnancy or recent lactation (< 1 year)

- Severe cardiac disease (New York Heart Association class III or greater), myocardial
infarction within 12 months, uncontrolled hypertension

- Verified osteoporosis (proximal femur or lumbar spine t-score < -2.5 or fracture
without trauma)

- Concomitant medications affecting calcium and bone metabolism such as
bisphosphonates, calcitonin, PTH, SERMs, oral corticosteroids (over 6 months),
anticonvulsants (fenytoin, carbamazepine) and prolonged heparin therapy

- Other diseases affecting calcium and bone metabolism such as hyperthyroidism, newly
diagnosed hypothyroidism, primary hyperparathyroidism, renal failure, chronic hepatic
diseases, organ transplant, Cushing's syndrome, rheumatoid arthritis, chronic bowel
diseases such as celiac disease, Chron disease or history of total ventricular
resection

- Other serious illness or medical condition, which could be contraindication for
exercise

- Patients not capable of training (severe knee arthrosis, severe ligamental or
cartilage injuries at lower extremities)

- Residence more than one hour from the exercise centre

- Competitive athlete